Top

Published in:

01-06-2019 | Original Article

Contribution of Apelin-17 to Collateral Circulation Following Cerebral Ischemic Stroke

Authors: Wan Jiang, Wei Hu, Li Ye, Yanghua Tian, Ren Zhao, Juan Du, Bing Shen, Kai Wang

Published in: Translational Stroke Research | Issue 3/2019

Abstract

Apelin, an essential mediator of homeostasis, is crucially involved in cardiovascular diseases, including ischemic stroke. However, the functional roles of apelin-17 in cerebral collateral circulation and ischemic stroke protection are unknown. Here, we investigated the association between plasma apelin-17 levels and collateral circulation in patients with ischemic stroke and examined the mechanism undergirding the effects of apelin-17 on cerebral artery contraction and ischemic stroke protection in an animal model. Plasma nitric oxide (NO), apelin-17, and apelin-36 levels were assessed by enzyme-linked immunosorbent assays in ischemic stroke patients with good or poor collateral circulation and in healthy participants. Additionally, the effects of apelin-17 on rat basilar artery contractions (in vitro) and cerebral ischemia (in vivo) were determined using vessel tension measurements and nuclear magnetic resonance, respectively. Patients with good collateral circulation had significantly higher plasma apelin-17 and apelin-36 levels than both patients with poor collateral circulation and healthy participants and plasma NO levels significantly higher than those in healthy participants. In vitro, apelin-17 pretreatment markedly attenuated U46619-induced rat basilar artery contractions in an endothelium-dependent manner. Additionally, NO production or guanylyl cyclase inhibitors abolished the apelin-17 effect on U46619-induced vascular contraction. Intravenous pretreatment of rats with apelin-17 markedly reduced cerebral infarct volume at 24 h after middle cerebral artery occlusion. Plasma apelin-17 levels in ischemic stroke patients were positively associated with enhanced collateral circulation, which our animal study data suggested may have resulted from an apelin-17-induced cerebral artery dilation mediated through the NO–cGMP pathway.

Mokin M, Snyder KV, Siddiqui AH, Levy EI, Hopkins LN. Recent endovascular stroke trials and their impact on stroke systems of care. J Am Coll Cardiol. 2016;67:2645–55. https://doi.org/10.1016/j.jacc.2015.12.077.CrossRefPubMed

Liebeskind DS. Collateral circulation. Stroke. 2003;34(9):2279–84. https://doi.org/10.1038/nrneurol.2009.193. CrossRefPubMed

Martinon E, Lefevre PH, Thouant P, Osseby GV, Ricolfi F, Chavent A. Collateral circulation in acute stroke: assessing methods and impact: a literature review. J Neuroradiol. 2014;41:97–107. https://doi.org/10.1016/j.neurad.2014.02.001.CrossRefPubMed

Liebeskind DS. Stroke: The currency of collateral circulation in acute ischemic stroke. Nat Rev Neurol. 2009;5:645–6. https://doi.org/10.1038/nrneurol.2009.193.CrossRefPubMed

Liu J, Wang Y, Akamatsu Y, Lee CC, Stetler RA, Lawton MT, et al. Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials. Prog Neurobiol. 2014;115:138–56. https://doi.org/10.1016/j.pneurobio.2013.11.004.CrossRef

Schramm P, Schellinger PD, Fiebach JB, Heiland S, Jansen O, Knauth M, et al. Comparison of ct and ct angiography source images with diffusion-weighted imaging in patients with acute stroke within 6 hours after onset. Stroke. 2002;33:2426–32. https://doi.org/10.1161/01.STR.0000032244.03134.37.CrossRefPubMed

Fischer U, Arnold M, Nedeltchev K, Brekenfeld C, Ballinari P, Remonda L, et al. Nihss score and arteriographic findings in acute ischemic stroke. Stroke. 2005;36(10):2121–5. https://doi.org/10.1161/01.STR.0000182099.04994.fc.CrossRefPubMed

Muir KW. Stroke in 2015: the year of endovascular treatment. Lancet Neurol. 2016;15:2–3.CrossRefPubMed

Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human apj receptor. Biochem Biophys Res Commun. 1998;251(2):471–6. https://doi.org/10.1006/bbrc.1998.9489.CrossRefPubMed

10.

Than A, He HL, Chua SH, Xu D, Sun L, Leow MK, et al. Apelin enhances brown adipogenesis and browning of white adipocytes. J Biol Chem. 2015;290(23):14679–91. https://doi.org/10.1074/jbc.M115.643817.CrossRefPubMedPubMedCentral

11.

Yang Y, Lv SY, Ye W, Zhang L. Apelin/apj system and cancer. Clin Chim Acta. 2016;457:112–6. https://doi.org/10.1016/j.cca.2016.04.001.CrossRef

12.

Wang C, Wen J, Zhou Y, Li L, Cui X, Wang J, et al. Apelin induces vascular smooth muscle cells migration via a pi3k/akt/foxo3a/mmp-2 pathway. Int J Biochem Cell Biol. 2015;69:173–82. https://doi.org/10.1016/j.biocel.2015.10.015.CrossRefPubMed

13.

Chapman NA, Dupre DJ, Rainey JK. The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class a gpcr. Biochem Cell Biol. 2014;92(6):431–40. https://doi.org/10.1139/bcb-2014-0072.CrossRefPubMedPubMedCentral

14.

Wang W, McKinnie SM, Farhan M, Paul M, McDonald T, McLean B, et al. Angiotensin-converting enzyme 2 metabolizes and partially inactivates pyr-apelin-13 and apelin-17: physiological effects in the cardiovascular system. Hypertension. 2016;68:365–77. https://doi.org/10.1161/HYPERTENSIONAHA.115.06892.CrossRefPubMed

15.

Yu XH, Tang ZB, Liu LJ, Qian H, Tang SL, Zhang DW, et al. Apelin and its receptor apj in cardiovascular diseases. Clin Chim Acta. 2014;428:1–8. https://doi.org/10.1016/j.cca.2013.09.001. CrossRefPubMed

16.

Zhong JC, Yu XY, Huang Y, Yung LM, Lau CW, Lin SG. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res. 2007;74(3):388–95. https://doi.org/10.1016/j.cardiores.2007.02.002.CrossRefPubMed

17.

Pisarenko OI, Lankin VZ, Konovalova GG, Serebryakova LI, Shulzhenko VS, Timoshin AA, et al. Apelin-12 and its structural analog enhance antioxidant defense in experimental myocardial ischemia and reperfusion. Mol Cell Biochem. 2014;391(1–2):241–50. https://doi.org/10.1007/s11010-014-2008-4.CrossRefPubMed

18.

Berry MF, Pirolli TJ, Jayasankar V, Burdick J, Morine KJ, Gardner TJ, et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004; 110(11 suppl 1):II187–93. doi:https://doi.org/10.1161/01.CIR.0000138382.57325.5c, II-187, II-193.

19.

Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99(2):87–92. https://doi.org/10.1016/S0167-0115(01)00236-1.CrossRefPubMed

20.

Kuklinska AM, Sobkowicz B, Sawicki R, Musial WJ, Waszkiewicz E, Bolinska S, et al. Apelin: a novel marker for the patients with first st-elevation myocardial infarction. Heart Vessel. 2010;25:363–7. https://doi.org/10.1007/s00380-009-1217-3.CrossRef

21.

Yang Y, Zhang XJ, Li LT, Cui HY, Zhang C, Zhu CH, et al. Apelin-13 protects against apoptosis by activating amp-activated protein kinase pathway in ischemia stroke. Peptides. 2016;75:96–100. https://doi.org/10.1016/j.peptides.2015.11.002.CrossRefPubMed

22.

Xin Q, Cheng B, Pan Y, Liu H, Yang C, Chen J, et al. Neuroprotective effects of apelin-13 on experimental ischemic stroke through suppression of inflammation. Peptides. 2015;63:55–62. https://doi.org/10.1016/j.peptides.2014.09.016.CrossRefPubMed

23.

Gu Q, Zhai L, Feng X, Chen J, Miao Z, Ren L, et al. Apelin-36, a potent peptide, protects against ischemic brain injury by activating the pi3k/akt pathway. Neurochem Int. 2013;63(6):535–40. https://doi.org/10.1016/j.neuint.2013.09.017.CrossRefPubMed

24.

Hu W, Jiang W, Ye L, Tian Y, Shen B, Wang K. Prospective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases. Sci Rep. 2017;7:5452. https://doi.org/10.1038/s41598-017-05664-8.CrossRefPubMedPubMedCentral

25.

Zhao R, Zhou M, Li J, Wang X, Su K, Hu J, et al. Increased trpp2 expression in vascular smooth muscle cells from high-salt intake hypertensive rats: the crucial role in vascular dysfunction. Mol Nutr Food Res. 2015;59(2):365–72. https://doi.org/10.1002/mnfr.201400465.CrossRefPubMed

26.

Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84–91. https://doi.org/10.1161/01.STR.20.1.84.CrossRef

27.

Jia YX, Lu ZF, Zhang J, Pan CS, Yang JH, Zhao J, et al. Apelin activates l-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides. 2007;28(10):2023–9. https://doi.org/10.1016/j.peptides.2007.07.016.CrossRefPubMed

28.

Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension. 2009;54:598–604. https://doi.org/10.1161/HYPERTENSIONAHA.109.134619.CrossRefPubMed

29.

Zhang YH. Nitric oxide signalling and neuronal nitric oxide synthase in the heart under stress. F1000Research 2017; 6:742. doi:https://doi.org/10.12688/f1000research.10128.1.

30.

Lv D, Li H, Chen L. Apelin and apj, a novel critical factor and therapeutic target for atherosclerosis. Acta Biochim Biophys Sin Shanghai. 2013;45(7):527–33. https://doi.org/10.1093/abbs/gmt040.CrossRefPubMed

31.

Yang Y, Zhang X, Cui H, Zhang C, Zhu C, Li L. Apelin-13 protects the brain against ischemia/reperfusion injury through activating pi3k/akt and erk1/2 signaling pathways. Neurosci Lett. 2014;568:44–9. https://doi.org/10.1016/j.neulet.2014.03.037.CrossRefPubMed

32.

Japp AG, Cruden NL, Amer DA, Li VK, Goudie EB, Johnston NR, et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008;52(11):908–13. https://doi.org/10.1016/j.jacc.2008.06.013.CrossRefPubMed

33.

Palmi M, Meini A. Role of the nitric oxide/cyclic gmp/ca2+ signaling pathway in the pyrogenic effect of interleukin-1beta. Mol Neurobiol. 2002;25(2):133–47. https://doi.org/10.1385/MN:25:2:133. CrossRefPubMed

34.

Vandael DH, Mahapatra S, Calorio C, Marcantoni A, Carbone E. Cav1.3 and cav1.2 channels of adrenal chromaffin cells: emerging views on camp/cgmp-mediated phosphorylation and role in pacemaking. Biochim Biophys Acta. 2013;1828(7):1608–18. https://doi.org/10.1016/j.bbamem.2012.11.013.CrossRefPubMed

Title: Contribution of Apelin-17 to Collateral Circulation Following Cerebral Ischemic Stroke
Authors: Wan Jiang
Wei Hu
Li Ye
Yanghua Tian
Ren Zhao
Juan Du
Bing Shen
Kai Wang
Publication date: 01-06-2019
Publisher: Springer US
Published in: Translational Stroke Research / Issue 3/2019
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-018-0638-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Contribution of Apelin-17 to Collateral Circulation Following Cerebral Ischemic Stroke

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Role of Exosomes as a Treatment and Potential Biomarker for Stroke

Electrocardiographic RR Interval Dynamic Analysis to Identify Acute Stroke Patients at High Risk for Atrial Fibrillation Episodes During Stroke Unit Admission

Radiological Estimation of Intracranial Blood Volume and Occurrence of Hydrocephalus Determines Stress-Induced Hyperglycemia After Aneurysmal Subarachnoid Hemorrhage

Early Inflammatory Response in the Brain and Anesthesia Recovery Time Evaluation After Experimental Subarachnoid Hemorrhage

Complement Complex C5b-9 Levels Are Associated with the Clinical Outcomes of Acute Ischemic Stroke and Carotid Plaque Stability

Effects of Barometric Pressure and Temperature on Acute Ischemic Stroke Hospitalization in Augusta, GA